Article

ASCO Global HPV Vaccination Guidelines Address Cervical Cancer Prevention

Clinical practice guideline on human papillomavirus (HPV) vaccination can improve prevention of cervical cancer.

The American Society of Clinical Oncology (ASCO) released a clinical practice guideline on human papillomavirus (HPV) vaccination for the primary prevention of cervical cancer. The updated guidelines are designed for different regions worldwide based on varying socio-economic and structural resource settings.

The recommendations are divided according to 4 levels of resource settings: basic, limited, enhanced, and maximal.

For all environments and independent of resource settings:

  • Two doses of HPV vaccine are recommended for girls aged 9-14 years old, with an interval of at least 6 months and up to 12-15 months between doses.
  • Girls who have HIV should receive 3 doses.

For maximal and enhanced resource settings:

  • If girls are 15 years or older and have received their first dose before age 15, they may complete the 2-dose series.
  • If they have no received first dose before age 15, they should receive 3 doses.
  • In both scenarios, vaccination may be given through age 26 years old.

For limited and basic resource settings:

  • If sufficient resources remain after vaccinating girls aged 9-14 years old, girls who received 1 dose may receive additional doses between ages 15-16 years old.

For vaccination of boys in all settings, boys may be vaccinated if there is at least 50% coverage in the priority female target population, sufficient resources, and such vaccination is cost-effective.

The guidelines were developed by a multinational and multidisciplinary panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts.

Reference

Arrossi S, Temin S, Garland S, et al. Primary prevention of cervical cancer. ASCO. Mar. 17, 2017. doi: 10.1200/JGO.2016.008151.

First Global Guidance for HPV Vaccination for Cervical Cancer Prevention [news release]. Virginia. ASCO’s website. http://www.asco.org/about-asco/press-center/news-releases/first-global-guidance-hpv-vaccination-cervical-cancer. Accessed Mar. 20, 2017.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards